Effects of a Potato-based Food Pattern vs a Rice / Pasta-based Food Pattern on Cardiometabolic Health (LoPoCardio)

April 14, 2021 updated by: Maastricht University Medical Center

Long-term Effects of a Potato-based Food Pattern vs a Rice / Pasta-based Food Pattern on Fasting & Postprandial Cardiometabolic Health; The LoPoCardio - Trial

The researchers investigate the effect of long-term (12-weeks) consumption of diets rich in boiled potatoes versus those rich in rice or pasta on established cardiovascular risk parameters. These carbohydrate sources will be part of a recommended healthy dietary pattern to mimic as closely as possible current dietary guidelines, facilitating the implementation of the outcomes.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

To breach the current controversies, there is an urgent need for well-designed controlled human intervention trials evaluating the true impact of boiled potato consumption as part of a healthy dietary pattern on cardiometabolic health. There are two important issues that need to be addressed when designing such an intervention study: First, the longer-term effects of boiled potato consumption on established fasting and postprandial cardiovascular risk markers should be addressed. Second, the effect of boiled potatoes should be studied using an iso-energetic exchange for other traditionally main carbohydrate sources. These carbohydrate-sources will be part of a recommended healthy dietary pattern to mimic as closely as possible current dietary guidelines, facilitating the implementation of the outcomes. Effects will be studied in both fasting and postprandial conditions. In fact, the evidence is accumulating that optimizing postprandial glucose and lipid responses are important targets for maintaining health. Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, the question is how long-term intake of these products affects the metabolic capacity of our body to respond to postprandial challenges. Interestingly, potatoes are not only rich in complex carbohydrates but are also more nutrient-dense (a wide variety of minerals, vitamins, and micronutrients) as compared to white rice and white pasta. In addition, potatoes provide large amounts of fiber and are more satiating than other carbohydrate sources. This nutrient profile might beneficially impact the resilience of the metabolic machinery and as such improve postprandial cardiometabolic plasma profiles (glucose, insulin, and triacylglycerol). In other words, there might be a beneficial effect of longer-term potato consumption in comparison with longer-term white pasta and white rice consumption will not only be present in fasting conditions but particularly in the postprandial state when the cardiometabolic system is challenged.

Study Type

Interventional

Enrollment (Anticipated)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The inclusion criteria are:
  • Aged between 40-70 years
  • Men and women
  • 18-70 years
  • BMI between 25-35 kg/m2 (overweight and obese)
  • Serum total cholesterol < 8.0 mmol/L (further testing is recommended for excessive hyperlipidemia [serum total cholesterol ≥ 8.0 mmol/L] according to the Standard for cardiovascular risk management of the Dutch general practitioners community [NHG])
  • Serum triacylglycerol < 4.5 mmol/L
  • No current smoker
  • No diabetic patients
  • No familial hypercholesterolemia
  • No abuse of drugs
  • Not more than 4 alcoholic consumption per day with a maximum of 21 per week??
  • Stable body weight (weight gain or loss < 3 kg in the past three months)
  • No use of medication known to treat blood pressure, lipid or glucose metabolism
  • No use of an investigational product within another biomedical intervention trial within the previous 1-month
  • No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
  • No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
  • Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
  • No difficult venipuncture as evidenced during the screening visit
  • Willing to comply to study protocol during study
  • Informed consent signed

Exclusion Criteria:

  • The exclusion criteria are:
  • Allergy or intolerance to potatoes, pasta or rice
  • Serum total cholesterol ≥ 8.0 mmol/L
  • Serum triacylglycerol ≥ 4.5 mmol/L
  • Current smoker, or smoking cessation <12 months
  • Diabetic patients
  • Familial hypercholesterolemia
  • Abuse of drugs
  • More than 4 alcoholic consumptions per day or 21 per week
  • Unstable body weight (weight gain or loss > 3 kg in the past three months)
  • Use medication known to treat blood pressure, lipid or glucose metabolism
  • Use of an investigational product within another biomedical intervention trial within the previous 1-month
  • Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
  • Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
  • Not willing to give up being a blood donor from 8 weeks before the start of the study, during the study or for 4 weeks after completion of the study
  • Not or difficult to venipuncture as evidenced during the screening visit
  • Use of over-the-counter and prescribed medication or supplements, which may interfere with study measurements to be judged by the principal investigator;
  • Use of oral antibiotics in 40 days or less prior to the start of the study;
  • Blood donation in the past 3 months before the start of the study
  • Not willing to comply to study protocol during study or sign informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Potato group
The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
Active Comparator: Pasta/rice

The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.

The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes.

Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chronic glucose metabolism
Time Frame: pre- intervention and post- intervention (12 weeks)
Measured by change in average daily glucose concentrations over a 15 hours period between waking up and going to bed 7:00AM - 22:00PM for three days, which is calculated based on the total area under the curve (tAUC) using a continuos glucose monitor.
pre- intervention and post- intervention (12 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lipid metabolism
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by fasting serum C-peptide, lipids and lipoproteins in all visits
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Glucose metabolism
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by fasting plasma glucose, insulin, and calculated HOMA- IR in all visits
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Low grade inflammation
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by inflammation plasma markers (hsCPR, IL6, IL8, TNFa)
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Postprandial glucose metabolism
Time Frame: 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Following a high-fat, high-carb meal, measured by plasma glucose, insulin.
12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Postprandial TAG metabolism
Time Frame: 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Following a high-fat, high-carb meal, measured by plasma TAG.
12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
24h urine samples micronutrient profiles
Time Frame: 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Measured by 24 urine collection.
12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Quality of life questionnaire
Time Frame: 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Assessed with a 32-item questionnaire (including social, spiritual, emotional, cognitive, physical, activities of daily living, and integrated quality of life)
12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Mood, degree of pleasantness and arousal
Time Frame: 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Assessed with the Affect grid
12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Fatigue
Time Frame: 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Assessed using the FSS, a 9-item questionnaire that is used to determine the severity of fatigue a subject experienced in the past week during daily activities
12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Cognitive performance
Time Frame: 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Assessed with a validated neuropsychological test battery (CANTAB)
12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Venular and arteriolar diameters
Time Frame: 12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Assessed via fundus photography
12 weeks intervention: Pre-intervention (visit 2), during the intervention (visit 4) and post intervention (visit 7)
Office blood pressure
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by office blood pressure monitor in all visits
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
36h blood pressure profiles
Time Frame: 12 weeks intervention: Pre- intervention (visit-1) and post- intervention (visit 6)
Assessed via wearables blood pressure monitor
12 weeks intervention: Pre- intervention (visit-1) and post- intervention (visit 6)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploratory objective endothelial (dys)function markers
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)

Measured by sE-selectin, sICAM, sVCAM, and MCP-1 in al visits

To investigate if potato consumption by overweight and obese (BMI25-35 kg/m2) men and women changes:

  • Endothelial (dys)function markers (sE-selectin, sICAM, sVCAM, and MCP-1) - Liver enzymes (e.g. ALAT, ASAT, gGT, bilirubin)
  • Calculated insulin secretory function (HOMA%B index)
  • Micro-albumineria and kidney function (estimated GFR)
  • Plasma incretins / satiety hormones (PYY, GLP, Ghrelin)
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Exploratory objective liver enzymes
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by liver enzymes (ALAT, ASAT, gGT, bilirubin)
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Exploratory objective calculated insulin secretory function
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by HOMA%B index
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Exploratory objective micro-albumineria and kidney function
Time Frame: 12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Measured by estimated GFR
12 weeks intervention: Pre-intervention (visit 1 and 2), during the intervention (visit 3, 4, 5) and post intervention (visit 6, and 7)
Exploratory objective plasma incretins / satiety hormones in fasting and postprandial conditions
Time Frame: 12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)
Following a high-fat, high-carb meal, measured by PYY, GLP, ghrelin.
12 weeks intervention: Pre-intervention (visit 2) and post intervention (visit 7)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jogchum J Plat, PhD, Chair of Nutrition and Movement Science Department
  • Principal Investigator: Ronald P. Mensisnk, PhD, Chair of Nutrition and Movement Science Department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2021

Primary Completion (Anticipated)

May 1, 2024

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

April 14, 2021

First Posted (Actual)

April 20, 2021

Study Record Updates

Last Update Posted (Actual)

April 20, 2021

Last Update Submitted That Met QC Criteria

April 14, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • METC19-067

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glucose Metabolism

Clinical Trials on Potato

3
Subscribe